WCM
CPRX

Wedge Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Wedge Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-145,168
Closed -$2.86M – 520
2025
Q3 		$2.86M Buy
+145,168
New +$2.99M 0.05% 278
2023
Q2 		– Sell
-14,978
Closed -$248K – 514
2023
Q1 		$248K Buy
14,978
+1,175
+9% +$19.4K ﹤0.01% 373
2022
Q4 		$257K Buy
13,803
+3,783
+38% +$58.2K ﹤0.01% 370
2022
Q3 		$129K Sell
10,020
-6,696
-40% -$79.4K ﹤0.01% 395
2022
Q2 		$117K Buy
16,716
+852
+5% +$6.25K ﹤0.01% 402
2022
Q1 		$132K Sell
15,864
-5,371
-25% -$38K ﹤0.01% 414
2021
Q4 		$144K Sell
21,235
-2,345
-10% -$15.4K ﹤0.01% 405
2021
Q3 		$125K Buy
23,580
+6,114
+35% +$33.4K ﹤0.01% 398
2021
Q2 		$100K Sell
17,466
-10,497
-38% -$54.2K ﹤0.01% 391
2021
Q1 		$129K Sell
27,963
-160,973
-85% -$640K ﹤0.01% 520
2020
Q4 		$631K Buy
188,936
+64,735
+52% +$217K 0.01% 374
2020
Q3 		$369K Sell
124,201
-2,473
-2% -$9.67K ﹤0.01% 412
2020
Q2 		$585K Buy
+126,674
New +$569K 0.01% 347

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wedge Capital Management's CPRX Position: Q4 2025 in Review

Wedge Capital Management sold out of Catalyst Pharmaceutical (CPRX) in Q4 2025, closing a stake of 145,168 shares — an estimated $2.86M sold.

Wedge Capital Management first reported a position in CPRX in Q2 2020 and held it in 13 quarters. The position peaked at $2.86M in Q3 2025. 373 funds tracked by Wall St. Rank hold CPRX as of Q4 2025.

  • Wedge Capital Management reported no remaining Catalyst Pharmaceutical position as of Q4 2025 after selling out during the quarter.
  • Wedge Capital Management sold 145,168 Catalyst Pharmaceutical shares in Q4 2025, an estimated $2.86M.
  • Wedge Capital Management first reported a position in Catalyst Pharmaceutical in Q2 2020 and held it in 13 quarters.
  • Wedge Capital Management's Catalyst Pharmaceutical position peaked at $2.86M in Q3 2025.
  • 373 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2025.

Based on Wedge Capital Management's 13F filing for Q4 2025, filed 14 Jan 2026.